Drug Profile

GQ 1007

Alternative Names: GQ-1007

Latest Information Update: 17 May 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Suzhou GeneQuantum Healthcare
Developer BrightGene Bio-medical technology; Suzhou GeneQuantum Healthcare
Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
Mechanism of Action Immunogenetic stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Cancer

Most Recent Events

15 May 2022 Ethics Committee approves clinical trials application for GQ 1005 in cancer
01 Apr 2022 GeneQuantum Healthcare plans a phase I trial for Solid tumor (Late-stage disease, Monotherapy, Combination therapy) in Australia (SC) in May 2022 (ACTRN12622000513718)
07 Sep 2021 GeneQuantum plans to files an IND application for Cancer

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com